# Low Dose Tamoxifen for Mammographic Density Reduction

> **NCT03346200** · PHASE2 · COMPLETED · sponsor: **Per Hall** · enrollment: 1440 (actual)

## Conditions studied

- Risk Reduction
- Mammographic Density Reduction

## Interventions

- **DRUG:** Tamoxifen Oral Tablet
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03346200
- **Lead sponsor:** Per Hall
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11
- **Primary completion:** 2019-10
- **Final completion:** 2019-12
- **Target enrollment:** 1440 (ACTUAL)
- **Last updated:** 2025-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03346200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03346200, "Low Dose Tamoxifen for Mammographic Density Reduction". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03346200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*